SecBot SecBot
PRESS-RELEASE ·Filed May 7, 2026

VCEL

Vericel Corporation
BULLISH
Impact 8/10
Horizonweeks Processed6mo ago WireGlobeNewswire
Press release · Earnings
Actionable Insight ▲ Bullish

The combination of a strong revenue beat, raised guidance, positive free cash flow inflection, and the BARDA award creates a powerful bullish catalyst. Watch for continued MACI implant growth and MHRA submission progress in 2026 as next catalysts. The stock should re-rate higher given the cash flow inflection and raised outlook.

DirectionBullish
Confidencehigh
Horizonweeks

How the stock moved after the report

BULLISH VIEWSTOCK ABOVE ENTRY AT T+60
Entry
$35.13
T+0 close · May 7, 2026 · via day close
Latest settled
+31.08%
T+60 · $46.05
Vs SPY
+27.25%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · May 7 $35.13entry
  2. T+1 · 6mo ago −4.75%α −5.58% · $33.46
  3. T+5 · 6mo ago −6.52%α −8.02% · $32.84
  4. T+20 · 6mo ago −1.11%α −4.25% · $34.74
  5. T+60 · 4mo ago +31.08%α +27.25% · $46.05
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Vericel reported Q1 2026 revenue of $68.4M (+30% YoY) and GAAP EPS of -$0.12 (vs consensus -$0.16, a 25% beat on the loss). The company raised full-year 2026 revenue guidance by $10M to $326-336M, driven by 22% MACI growth and 91% Burn Care growth. Free cash flow turned positive at $15.1M vs -$7.6M a year ago, signaling an inflection in cash generation.

Key Financial Metrics

EPS
−$0.12
est −$0.16 · +25.0%
Revenue
$68.4M
est $63.6M · +7.6% · +30.1% YoY
Rating
strong beat
Guidance
$326M-$336M
raised
Free Cash Flow
$15.1M
Gross Margin
72%

Key Facts

  • Total revenue $68.4M (+30% YoY), above consensus $63.6M
  • GAAP EPS -$0.12 vs consensus -$0.16 (25% beat on loss)
  • MACI revenue $56.4M (+22% YoY), Burn Care $12.0M (+91% YoY)
  • Gross margin 72% vs 69% a year ago
  • Adjusted EBITDA $9.6M (+195% YoY), 14% of revenue
  • Operating cash flow $16.4M, free cash flow $15.1M (vs -$7.6M Q1 2025)
  • FY2026 revenue guidance raised to $326-336M from $316-326M
  • BARDA award up to $197M for NexoBrid procurement and development
  • FDA approval for MACI commercial manufacturing at new facility
  • Cash and investments $211M, no debt

Financial Impact

Revenue beat by ~$4.8M (7.5% above consensus), EPS beat by $0.04 on loss. Guidance raised by $10M at midpoint. Free cash flow swing of +$22.7M YoY.

revenueepsfree cash flowguidancegross margin

Risk Factors

  • GAAP net loss persists at -$6.3M despite operational improvements
  • Selling expenses increased to $49.2M (+18% YoY) as sales force expands
  • Dependence on MACI for ~82% of revenue concentration risk
  • Geopolitical risks to NexoBrid supply from MediWound in Israel

Market Snapshot

Exchange
Nasdaq
Sector
Biological Products, (No Diagnostic Substances)
Analyst Consensus
86% bullish (14 analysts)

Investment Themes

Documents Analyzed

This report is based on 1 press release from GlobeNewswire.

DocumentAccession Number
PRESS-RELEASE Data (Synthetic)press-3289900

US Market Status

Market Closed · Opens in 6h 36m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published May 7, 2026